[
  {
    "ts": "2025-10-20T15:06:00+00:00",
    "headline": "RANI: Chugai Deal Announced",
    "summary": "By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT With investors perched on the edge of their seats for months, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18 th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront",
    "url": "https://finance.yahoo.com/news/rani-chugai-deal-announced-150600311.html",
    "source": "Zacks Small Cap Research",
    "provider": "yfinance",
    "raw": {
      "id": "109b21a8-1417-3de0-b573-30463f19ed5b",
      "content": {
        "id": "109b21a8-1417-3de0-b573-30463f19ed5b",
        "contentType": "STORY",
        "title": "RANI: Chugai Deal Announced",
        "description": "",
        "summary": "By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT With investors perched on the edge of their seats for months, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18 th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront",
        "pubDate": "2025-10-20T15:06:00Z",
        "displayTime": "2025-10-20T15:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/scr.zacks.com/1ddd6a2a554124b13fe057e1436fa693",
          "originalWidth": 2204,
          "originalHeight": 822,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rqdOXWH5rtEv6MVaHXw5Gw--~B/aD04MjI7dz0yMjA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/1ddd6a2a554124b13fe057e1436fa693.cf.webp",
              "width": 2204,
              "height": 822,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4N.1EFEMVBfsV5STVag3LA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/1ddd6a2a554124b13fe057e1436fa693.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks Small Cap Research",
          "url": "http://scr.zacks.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rani-chugai-deal-announced-150600311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rani-chugai-deal-announced-150600311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4519.T"
            },
            {
              "symbol": "RANI"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "IOT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T11:02:34+00:00",
    "headline": "ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer",
    "summary": "These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-verzenio-hr-her2-breast-cancer-os-phase-iii/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "7cce1ac5-07e9-38be-9b34-6752769b3e1e",
      "content": {
        "id": "7cce1ac5-07e9-38be-9b34-6752769b3e1e",
        "contentType": "STORY",
        "title": "ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer",
        "description": "",
        "summary": "These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.",
        "pubDate": "2025-10-20T11:02:34Z",
        "displayTime": "2025-10-20T11:02:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/f745e5a94ecc3d77e053dc561c447bba",
          "originalWidth": 2121,
          "originalHeight": 1414,
          "caption": "Eli Lilly's CDK 4/6 inhibitor",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n3d60shm.jUagCeLGMGXOQ--~B/aD0xNDE0O3c9MjEyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/pharmaceutical_technology_376/f745e5a94ecc3d77e053dc561c447bba.cf.webp",
              "width": 2121,
              "height": 1414,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SjoJXsKubPA28vaJvH781Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/f745e5a94ecc3d77e053dc561c447bba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-verzenio-hr-her2-breast-cancer-os-phase-iii/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/esmo-2025-eli-lilly-verzenio-110234039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T08:20:00+00:00",
    "headline": "These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond",
    "summary": "These companies are jockeying for position in a potential $150 billion market opportunity.",
    "url": "https://www.fool.com/investing/2025/10/20/obesity-drug-stocks-set-to-soar-fall-lly-nvo-vktx/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d3de84a9-ce88-34bc-a78f-af2afa82896e",
      "content": {
        "id": "d3de84a9-ce88-34bc-a78f-af2afa82896e",
        "contentType": "STORY",
        "title": "These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond",
        "description": "",
        "summary": "These companies are jockeying for position in a potential $150 billion market opportunity.",
        "pubDate": "2025-10-20T08:20:00Z",
        "displayTime": "2025-10-20T08:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/23e8f6b49af14d1738f82a6ec437fa8e",
          "originalWidth": 6000,
          "originalHeight": 4000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VCx3M4YHlDCo8etZhJqvVg--~B/aD00MDAwO3c9NjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/23e8f6b49af14d1738f82a6ec437fa8e.cf.webp",
              "width": 6000,
              "height": 4000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wG.Dnv1NL_618_nJ1Dtp6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/23e8f6b49af14d1738f82a6ec437fa8e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/20/obesity-drug-stocks-set-to-soar-fall-lly-nvo-vktx/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-obesity-drug-stocks-set-082000983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]